Oral Oncology
Volume 40, Issue 7 , Pages 728-735, August 2004

Fatty acid synthase is required for the proliferation of human oral squamous carcinoma cells

  • Michelle Agostini

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
  • ,
  • Sabrina D. Silva

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
  • ,
  • Karina G. Zecchin

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
  • ,
  • Ricardo D. Coletta

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
  • ,
  • Jacks Jorge

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
  • ,
  • Massimo Loda

      Affiliations

    • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
  • ,
  • Edgard Graner

      Affiliations

    • Department of Oral Diagnosis, School of Dentistry of Piracicaba, UNICAMP, Av. Limeira 901, CP 52, Areão, Piracicaba, SP 13414-018, Brazil
    • Corresponding Author InformationCorresponding author. Tel.: +55-19-3412-5318; fax: +55-19-3412-5218

Received 10 December 2003; accepted 7 January 2004.

Abstract 

Fatty acid synthase (FAS) is the enzyme responsible for the endogenous synthesis of saturated long-chain fatty acids from the precursors acetyl-CoA and malonyl-CoA. A growing body of evidence indicates that FAS is over expressed in several human cancers, such as prostate, breast, bladder, liver, lung, melanoma and oral squamous cell carcinoma (SCC). In the present study we used human oral SCC cell lines (SCC-4, -9, -15 and -25) as a model to investigate the role of FAS in the pathogenesis of oral cancer. RT-PCR and western blot experiments demonstrated that FAS is differentially expressed by the four oral SCC cell lines, with the highest production in SCC-9 followed by SCC-25. FAS expression in SCC-4 and -15 was similarly lower than the other cell lines. Proliferation curves and immunocytochemistry for PCNA and Ki-67 demonstrated that SCC-25 has the highest proliferative potential. In addition, the specific inhibitor of FAS activity cerulenin was able to significantly reduce the proliferation of oral SCC cells. Expression of androgen receptor was low in SCC-4, -9 and -15 and undetectable in SCC-25, whereas EGFR and c-erb-B2 were expressed in high amounts by the four cell lines. Immunocytochemical reactions showed that SCC-25 expresses higher levels of EGF compared to the other three cell lines. Finally, oral SCC cells exposed to nanomolar concentrations of exogenous EGF presented a reduction in the FAS protein levels concomitant with a decrease in their proliferation rates. Taken together, our results indicate that FAS is expressed in an apparently androgen-independent fashion in oral SCC cells and it is necessary for their proliferation.

Keywords:  Oral squamous cell carcinoma, Fatty acid synthase, Cerulenin, c-erb-B2, EGFR, Oral cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(04)00027-2

doi:10.1016/j.oraloncology.2004.01.011

Oral Oncology
Volume 40, Issue 7 , Pages 728-735, August 2004